On December 4, 2023, Suma Krishnan, an insider at Krystal Biotech, Inc. (NASDAQ: KRYS), sold 25,000 shares of the company’s stock in a transaction valued at approximately $5.5 million. The shares were sold at an average price of $220.16 each. Following this sale, Krishnan retains ownership of 1,413,711 shares, which are currently valued at about $311.2 million. This transaction reflects a 1.74% decrease in Krishnan’s holdings in the company.
The sale has been officially recorded in a filing with the U.S. Securities and Exchange Commission (SEC), accessible for public view.
Stock Performance and Market Analysis
In trading on December 5, 2023, shares of Krystal Biotech experienced positive momentum, rising by $12.17 to reach $234.13 during the mid-day session. The stock saw a total of 537,880 shares exchanged, significantly surpassing its average trading volume of 326,125 shares.
Krystal Biotech’s stock performance is notable, with a market capitalization of approximately $6.79 billion. The company’s price-to-earnings ratio stands at 35.10, and it has a relatively low beta of 0.48, indicating less volatility compared to the broader market. Over the past year, the stock has fluctuated between a low of $122.80 and a high of $234.65.
On November 3, 2023, Krystal Biotech reported its quarterly earnings, revealing earnings per share (EPS) of $2.66, significantly exceeding analysts’ expectations of $1.12 by $1.54. The company generated revenue of $97.80 million, surpassing the anticipated $93.72 million. This impressive financial performance is underscored by a return on equity of 19.36% and a net margin of 53.30%. Analysts project the company will achieve an EPS of $6.14 for the current fiscal year.
Institutional Investment Activity
Several institutional investors have made significant adjustments to their holdings in Krystal Biotech. Soleus Capital Management L.P. increased its stake by 108.9% in the second quarter, acquiring an additional 481,200 shares to reach a total of 922,958 shares valued at approximately $126.87 million.
Additionally, UBS Asset Management expanded its holdings by 173.8% during the first quarter, now owning 575,506 shares valued at about $103.76 million. Braidwell LP also raised its position by 81.6%, while Norges Bank and Nuveen LLC each acquired new stakes valued at approximately $38.86 million and $42.22 million, respectively. Currently, institutions hold 86.29% of the stock.
Krystal Biotech is a commercial-stage biotechnology firm focused on developing genetic medicines for patients with rare diseases. The company markets its flagship product, VYJUVEK (beremagene geperpavec-svdt or B-VEC), specifically for treating dystrophic epidermolysis bullosa (DEB).
For those interested in staying updated on Krystal Biotech and related companies, a daily newsletter summarizing the latest news and analysts’ ratings is available through MarketBeat.com.
